ATE377010T1 - Caspase-inhibitoren und ihre verwendungen - Google Patents

Caspase-inhibitoren und ihre verwendungen

Info

Publication number: ATE377010T1
Authority: AT; Austria
Prior art keywords: group; ring; hydrogen; aliphatic; caspase inhibitors
Prior art date: 2000-06-07

Application number

AT01941972T

Other languages

English (en)

Inventor

Jean-Damien Charrier

Guy Brenchley

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-07

Filing date

2001-06-05

Publication date

2007-11-15

2001-06-05 Application filed by Vertex Pharma filed Critical Vertex Pharma

2007-11-15 Application granted granted Critical

2007-11-15 Publication of ATE377010T1 publication Critical patent/ATE377010T1/de

Links

102000011727 Caspases Human genes 0.000 title abstract 3
108010076667 Caspases Proteins 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title abstract 2
229910052799 carbon Inorganic materials 0.000 abstract 4
125000001931 aliphatic group Chemical group 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000035196 congenital hypomyelinating 2 neuropathy Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
150000002431 hydrogen Chemical group 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical compound C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Toxicology (AREA)

AT01941972T 2000-06-07 2001-06-05 Caspase-inhibitoren und ihre verwendungen ATE377010T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20992900P	2000-06-07	2000-06-07

Publications (1)

Publication Number	Publication Date
ATE377010T1 true ATE377010T1 (de)	2007-11-15

Family

ID=22780912

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01941972T ATE377010T1 (de)	2000-06-07	2001-06-05	Caspase-inhibitoren und ihre verwendungen

Country Status (11)

Country	Link
US (3)	US7407964B2 (de)
EP (1)	EP1289993B9 (de)
JP (1)	JP2003535865A (de)
KR (1)	KR20030025235A (de)
AT (1)	ATE377010T1 (de)
AU (2)	AU7527901A (de)
CA (1)	CA2409015A1 (de)
DE (1)	DE60131160T2 (de)
ES (1)	ES2295171T3 (de)
IL (1)	IL152845A0 (de)
WO (1)	WO2001094351A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2369619A1 (en)	1999-04-09	2000-10-19	Cytovia, Inc.	Caspase inhibitors and the use thereof
PT1163208E (pt)	1999-08-06	2004-08-31	Vertex Pharma	Inibidores de caspase e as suas utilizacoes
US6495522B1 (en)	1999-08-27	2002-12-17	Cytovia, Inc.	Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
PE20011350A1 (es)	2000-05-19	2002-01-15	Vertex Pharma	PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
DE60131160T2 (de) *	2000-06-07	2008-08-07	Vertex Pharmaceuticals Inc., Cambridge	Caspase-inhibitoren und ihre verwendungen
EP1485107A1 (de)	2002-02-11	2004-12-15	Vertex Pharmaceuticals Incorporated	Phospholipide als caspase-hemmer-prodrugs
EP1499898A2 (de) *	2002-04-19	2005-01-26	Vertex Pharmaceuticals Incorporated	Regulierung von tnf-alpha
PE20040728A1 (es)	2002-06-28	2004-10-23	Vertex Pharma	Inhibidores de caspasa
US7612091B2 (en)	2002-12-20	2009-11-03	Vertex Pharmaceuticals Incorporated	Caspase inhibitors and uses thereof
WO2004058756A1 (en)	2002-12-27	2004-07-15	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
JPWO2004073742A1 (ja) *	2003-02-24	2006-06-01	第一製薬株式会社	Ｂ型肝炎ウイルスｘ相互作用蛋白質の分解阻害剤
PE20050159A1 (es)	2003-05-27	2005-04-19	Vertex Pharma	Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
IL158599A0 (en) *	2003-10-26	2004-05-12	Yeda Res & Dev	Methods of modulating hematopoiesis
RU2382780C2 (ru) *	2004-02-27	2010-02-27	Вертекс Фармасьютикалз Инкорпорейтед	Ингибиторы каспаз и их применение
AU2005223767B2 (en) *	2004-03-12	2011-12-01	Vertex Pharmaceuticals Incorporated	Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PL217743B1 (pl) *	2004-05-15	2014-08-29	Vertex Pharma	Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw
CN1980658A (zh)	2004-05-27	2007-06-13	沃泰克斯药物股份有限公司	治疗自身炎性疾病的ice抑制剂
ES2312012T3 (es) *	2004-09-17	2009-02-16	Biomas Ltd.	Nuevos compuestos de telurio y su uso como inmunomodulares.
KR20080038369A (ko) *	2005-07-28	2008-05-06	버텍스 파마슈티칼스 인코포레이티드	카스파제 억제제 프로드럭
JP2009521458A (ja) *	2005-12-22	2009-06-04	シェーリングコーポレイション	トロンビン受容体アンタゴニストとしてのオキサゾロイソキノリン誘導体
EP2288615B1 (de)	2008-05-21	2017-06-21	Genesis Technologies Limited	Selektive caspasehemmer und ihre verwendung
US8518942B2 (en)	2008-08-06	2013-08-27	Buck Institute For Research On Aging	Caspase inhibitors and uses thereof
EP2221299A3 (de)	2009-02-11	2010-11-03	Dr. Reddy's Laboratories Ltd.	Herstellung von Cilazapril-Zwischenprodukten
US9045524B2 (en)	2009-05-21	2015-06-02	Novagenesis Foundation	Selective caspase inhibitors and uses thereof
CN101580505B (zh) *	2009-05-27	2014-09-10	沈阳药科大学	吡咯并[2，1-b]喹唑啉类天然产物的衍生物及其制备方法和用途
US9365612B2 (en)	2010-01-29	2016-06-14	United States Of America As Represented By The Secretary, Department Of Health And Human Services	Caspase inhibitors
JP6006908B2 (ja)	2010-11-05	2016-10-12	ブランダイスユニバーシティＢｒａｎｄｅｉｓＵｎｉｖｅｒｓｉｔｙ	Ｉｃｅ阻害化合物およびその使用
DK2697246T3 (en)	2011-04-15	2018-05-28	Genesis Tech Limited	SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF
US9956260B1 (en)	2011-07-22	2018-05-01	The J. David Gladstone Institutes	Treatment of HIV-1 infection and AIDS
US8729263B2 (en)	2012-08-13	2014-05-20	Novartis Ag	1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CN105636953B (zh) *	2013-07-31	2018-01-02	诺华股份有限公司	1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
MX2016014731A (es)	2014-05-12	2017-05-04	Conatus Pharmaceuticals Inc	Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
WO2017079566A1 (en)	2015-11-05	2017-05-11	Conatus Pharmaceuticals, Inc.	Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko)	2015-12-31	2018-09-12	코나터스 파마슈티칼스, 인크.	간 질환의 치료에서의 카스파제 억제제의 사용 방법
MX2019003889A (es)	2016-10-05	2019-08-12	Novartis Ag	Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
WO2022123062A1 (en)	2020-12-11	2022-06-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT377586B (de) *	1981-06-30	1985-04-10	Erba Farmitalia	Verfahren zur herstellung von substituierten pyrrolo-(2,1-b)-chinazolinen und pyrido(2,1-b)chinazolinen
US5552400A (en) *	1994-06-08	1996-09-03	Sterling Winthrop Inc.	Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5716929A (en) *	1994-06-17	1998-02-10	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
JP2000501428A (ja) *	1996-09-12	2000-02-08	アイドゥンファーマシューティカルズ，インコーポレイテッド	酵素のｉｃｅ／ｃｅｄ−３プロテアーゼファミリーを阻害する新規な三環式化合物
BR9712987A (pt) *	1996-10-11	2000-04-18	Warner Lambert Co	Inibidores de enzima de conversão de interleucina-1beta de sulfonamida
CA2268098A1 (en) *	1996-10-11	1998-04-23	Warner-Lambert Company	Aspartate ester inhibitors of interleukin-1.beta. converting enzyme
AU1915399A (en) *	1998-07-10	2000-02-01	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
DE60131160T2 (de) *	2000-06-07	2008-08-07	Vertex Pharmaceuticals Inc., Cambridge	Caspase-inhibitoren und ihre verwendungen

2001
- 2001-06-05 DE DE60131160T patent/DE60131160T2/de not_active Expired - Lifetime
- 2001-06-05 EP EP01941972A patent/EP1289993B9/de not_active Expired - Lifetime
- 2001-06-05 AU AU7527901A patent/AU7527901A/xx active Pending
- 2001-06-05 KR KR1020027016636A patent/KR20030025235A/ko not_active Withdrawn
- 2001-06-05 JP JP2002501900A patent/JP2003535865A/ja active Pending
- 2001-06-05 AU AU2001275279A patent/AU2001275279B2/en not_active Ceased
- 2001-06-05 AT AT01941972T patent/ATE377010T1/de not_active IP Right Cessation
- 2001-06-05 IL IL15284501A patent/IL152845A0/xx unknown
- 2001-06-05 ES ES01941972T patent/ES2295171T3/es not_active Expired - Lifetime
- 2001-06-05 CA CA002409015A patent/CA2409015A1/en not_active Abandoned
- 2001-06-05 WO PCT/US2001/018243 patent/WO2001094351A1/en not_active Ceased
- 2001-06-07 US US09/877,832 patent/US7407964B2/en not_active Expired - Fee Related
2008
- 2008-07-01 US US12/165,952 patent/US7829561B2/en not_active Expired - Fee Related
2010
- 2010-09-16 US US12/883,424 patent/US7968716B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20030025235A (ko)	2003-03-28
JP2003535865A (ja)	2003-12-02
AU2001275279B2 (en)	2007-01-04
IL152845A0 (en)	2003-06-24
WO2001094351A1 (en)	2001-12-13
EP1289993B1 (de)	2007-10-31
DE60131160D1 (de)	2007-12-13
US7968716B2 (en)	2011-06-28
US7407964B2 (en)	2008-08-05
EP1289993A1 (de)	2003-03-12
CA2409015A1 (en)	2001-12-13
US7829561B2 (en)	2010-11-09
US20110003824A1 (en)	2011-01-06
US20090023739A1 (en)	2009-01-22
AU7527901A (en)	2001-12-17
DE60131160T2 (de)	2008-08-07
ES2295171T3 (es)	2008-04-16
EP1289993B9 (de)	2008-08-20
US20020045623A1 (en)	2002-04-18

Legal Events

Date	Code	Title	Description
2008-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60131160D1 (de)	2007-12-13	Caspase-inhibitoren und ihre verwendungen
ATE232873T1 (de)	2003-03-15	Phosphonsaürederivate als ptp-1b-inhibitoren
AP2002002407A0 (en)	2002-03-31	Caspase inhibitors and uses thereof.
ATE253545T1 (de)	2003-11-15	Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
EA200100972A1 (ru)	2002-02-28	Новые соединения и композиции как ингибиторы протеаз
DE69928697D1 (de)	2006-01-05	Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
ATE443043T1 (de)	2009-10-15	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
CY1109227T1 (el)	2014-07-02	Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων
NL300175I2 (nl)	2005-05-02	Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
FI970246A7 (fi)	1997-01-21	Dihydrobentsofuraanit
ATE331708T1 (de)	2006-07-15	Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
BG107120A (bg)	2003-05-30	Нови бавнодействащи бетамиметици, метод за тяхното получаване и приложението им като лекарствени средства
ATE244717T1 (de)	2003-07-15	Inhibitoren des impdh-enzyms
DE60132309D1 (de)	2008-02-21	Amin-derivate zur behandlung von apoptosis
ATE326454T1 (de)	2006-06-15	Neue bernsteinsäure derivative als cysteine- protease-inhibitoren
ATE311380T1 (de)	2005-12-15	Durch säuregruppen disubstitierte heteroaryl- derivate und ihre verwendung als matrix metalloproteinas inhibitoren
ATE413388T1 (de)	2008-11-15	Muskarin antagonisten
ATE517861T1 (de)	2011-08-15	Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE266623T1 (de)	2004-05-15	Caspase inhibitoren und deren verwendung
ATE452884T1 (de)	2010-01-15	Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
NO934718L (no)	1994-06-23	Nye HIV protease inhibitorer
DE60002733D1 (de)	2003-06-18	Diester prodrugs von decahydroischinoline-3-carbonsäure
DE60215368D1 (de)	2006-11-23	Pyranderivate als inhibitoren von ace und nep
ATE223376T1 (de)	2002-09-15	Bisarylcyclobutenderivate als cyclooxygenasehemmer
ATE148109T1 (de)	1997-02-15	Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids